Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eric B Haura

Showing results (101-110 of 201) with videos related to

Pageof 21
Sort By:
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Molecular Cancer Therapeutics|September 6, 2014
Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsManuela Gridling, Scott B Ficarro, Florian P Breitwieser, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung CancerRyoji Kato, Hitendra S Solanki, Hilal Ozakinci, et al.
Cancer|September 9, 2020
Preventing smoking relapse in patients with cancer: A randomized controlled trialVani N Simmons, Steven K Sutton, Lauren R Meltzer, et al.
Nature Chemical Biology|March 2, 2010
A chemical and phosphoproteomic characterization of dasatinib action in lung cancerJiannong Li, Uwe Rix, Bin Fang, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
Pageof 21

Showing results (101-110 of 201) with videos related to

Sort By:
Pageof 21
Journal of Immunotherapy (Hagerstown, Md. : 1997)|September 3, 2013
Phase II trial of a GM-CSF-producing and CD40L-expressing bystander cell line combined with an allogeneic tumor cell-based vaccine for refractory lung adenocarcinomaBen C Creelan, Scott Antonia, David Noyes, et al.
Cell Chemical Biology|October 17, 2023
Differential network analysis of ROS1 inhibitors reveals lorlatinib polypharmacology through co-targeting PYK2Yi Liao, Lily L Remsing Rix, Xueli Li, et al.
Molecular Cancer Therapeutics|September 6, 2014
Identification of kinase inhibitor targets in the lung cancer microenvironment by chemical and phosphoproteomicsManuela Gridling, Scott B Ficarro, Florian P Breitwieser, et al.
Nature Chemical Biology|October 10, 2017
Polypharmacology-based ceritinib repurposing using integrated functional proteomicsBrent M Kuenzi, Lily L Remsing Rix, Paul A Stewart, et al.
Cancer|February 27, 2008
Phase 2 trial of docetaxel and gefitinib in the first-line treatment of patients with advanced nonsmall-cell lung cancer (NSCLC) who are 70 years of age or olderGeorge R Simon, Martine Extermann, Alberto Chiappori, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 21, 2025
In Situ RAS:RAF Binding Correlates with Response to KRASG12C Inhibitors in KRASG12C-Mutant Non-Small Cell Lung CancerRyoji Kato, Hitendra S Solanki, Hilal Ozakinci, et al.
Cancer|September 9, 2020
Preventing smoking relapse in patients with cancer: A randomized controlled trialVani N Simmons, Steven K Sutton, Lauren R Meltzer, et al.
Nature Chemical Biology|March 2, 2010
A chemical and phosphoproteomic characterization of dasatinib action in lung cancerJiannong Li, Uwe Rix, Bin Fang, et al.
ACS Chemical Biology|November 13, 2013
GSK3 alpha and beta are new functionally relevant targets of tivantinib in lung cancer cellsLily L Remsing Rix, Brent M Kuenzi, Yunting Luo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancerEric B Haura, Tawee Tanvetyanon, Alberto Chiappori, et al.
Pageof 21